Array refocuses, cuts 20% of staff; loses Amgen partnership
This article was originally published in Scrip
Executive Summary
Array BioPharma CEO Ron Squarer said it would be "unfortunate" for discontinuation of a non-core partnership with Amgen and an unrelated 20% staff reduction to distract from late-stage progress in the Boulder, Colorado-based company's clinical development pipeline.